Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2019 08:00 ET | Source: Immuron Limited

Immuron to Commence US Non-Deal Institutional Investor Roadshow

MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
June 12, 2019 07:00 ET | Source: Immuron Limited

US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study

Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
May 30, 2019 08:00 ET | Source: Immuron Limited

Immuron Announces the Closing of Public Offering of ADSs

MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin...
May 23, 2019 21:10 ET | Source: Immuron Limited

Immuron Prices Underwritten Public Offering of ADSs

MELBOURNE, Australia,, May 23, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
May 23, 2019 16:45 ET | Source: Immuron Limited

Immuron Announces Proposed Public Offering of ADSs

MELBOURNE, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin...
April 30, 2019 14:36 ET | Source: Immuron Limited

Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019

MELBOURNE, Australia, April 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
April 17, 2019 09:00 ET | Source: Immuron Limited

Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors

MELBOURNE, Australia, April 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
April 15, 2019 09:00 ET | Source: Immuron Limited

Immuron sales surge by 66% in the Third Quarter of FY19

Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
April 11, 2019 10:00 ET | Source: Immuron Limited

Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile

C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
April 11, 2019 09:00 ET | Source: Immuron Limited

Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea

Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...